Nanotechnology in Drug Delivery

The Nanobiotechnology Handbook

Volumn , Issue , 2012, Pages 519-534

  Cho, Jungmin ^a,b   Kim, Sungwon ^a,b   Park, Kinam ^a,b  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85002612299     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b12935-28     Document Type: Chapter

References (68)

1. Acharya, G., C. S. Shin, M. McDermott et al. 2010. The hydrogel template method for fabrication of homogeneous nano/microparticles. Journal of Controlled Release 141:314-319.
2. Adis. 2007. Megestrol acetate NCD oral suspension-Par pharmaceutical: Megestrol acetate nanocrystal dispersion oral suspension, PAR 100.2, PAR-100.2. In Drugs in R&D. Adis Data Information BV.
3. ALHaj, N. A., P. Abdullah, S. Ibrahim, and A. Bustamam. 2008. Tamoxifen drug loading solid lipid nanoparticles prepared by hot high pressure homogenization techniques. American Journal of Pharmacology and Toxicology 3(3):219-224.
4. Allen, C., N. Dos Santos, R. Gallagher, et al. 2002. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Bioscience Reports 22(2):225-250.
5. Anton, N., J. P. Benoit, and P. Saulnier. 2008. Design and production of nanoparticles formulated from nano-emulsion templates-a review. Journal of Controlled Release 128: 185-199.
6. Anton, N., P. Saulnier, C. Gaillard et al. 2009. Aqueous-core lipid nanocapsules for encapsulating fragile hydrophilic and/or lipophilic molecules. Langmuir 25(19):11413-11419.
7. Araujo, L., M. Sheppard, R. Löbenberg, and J. Kreuter. 1999. Uptake of PMMA nanoparticles from the gastrointestinal tract after oral administration to rats: Modification of the body distribution after suspension in surfactant solutions and in oil vehicles. International Journal of Pharmaceutics 176(12):209-224.
8. Barratt, G. M. 2000. Therapeutic applications of colloidal drug carriers. Pharmaceutical Science & Technology Today 3(5):163-171.
9. Barratt, G. 2003. Colloidal drug carriers: Achievements and perspectives. Cellular and Molecular Life Sciences 60(1):21-37.
10. Bawa, R. A. J. 2008. Nanoparticle-based therapeutics in humans: A survey. Nanotechnology Law & Business 5(2):135-155.
11. Bawa, R., S. R. Bawa, S. B. Maebius, T. Flynn, and C. Wei. 2005. Protecting new ideas and inventions in nanomedicine with patents. Nanomedicine 1(2):150-158.
12. Blazek-Welsh, A. I. and D. G. Rhodes. 2001. SEM imaging predicts quality of niosomes from maltodextrin-based proniosomes. Pharmaceutical Research 18(5):656-661.
13. Borchardt, R. T., J. Aube, T. J. Siahaan, S. Gangwar, and G. M. Pauletti. 1997. Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies. Advanced Drug Delivery Reviews 27(2-3):235-256.
14. Brayden, D. J., M. A. Jepson, and A. W. Baird. 2005. Keynote review: Intestinal Peyer’s patch M cells and oral vaccine targeting. Drug Discovery Today 10(17):1145-1157.
15. von Burkersroda, F., R. Gref, and A. Gopferich. 1997. Erosion of biodegradable block copolymers made of poly(D, L-lactic acid) and poly(ethylene glycol). Biomaterials 18(24):1599-1607.
16. Coon, J. S., W. Knudson, K. Clodfelter, B. Lu, and R. S. Weinstein. 1991. Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance. Cancer Research 51(3):897-902.
17. Desai, M. P., V. Labhasetwar, E. Walter, R. J. Levy, and G. L. Amidon. 1997. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharmaceutical Research 14(11):1568-1573.
18. Deschamps, B., N. Musaji, and J. A. Gillespie. 2009. Food effect on the bioavailability of two distinct formulations of megestrol acetate oral suspension. International Journal of Nanomedicine 4:185-192.
19. Devalapally, H., A. Chakilam, and M. M. Amiji. 2007. Role of nanotechnology in pharmaceutical product development. Journal of Pharmaceutical Sciences 96(10):2547-2565.
20. Dingler, A. and S. Gohla. 2002. Production of solid lipid nanoparticles (SLN): Scaling up feasibilities. Journal of Microencapsulation 19(1):11-16.
21. Dubin, C. H. 2004. Special delivery: Pharmaceutical companies aim to target their drugs with nano precision. Mechanical Engineering Magazine 126(Suppl):10-12.
22. Fang, J. Y., T. L. Hwang, and Y. L. Huang. 2006. Liposomes as vehicles for enhancing drug delivery via skin routes. Current Nanoscience 2(1):55-70.
23. Garcion, E., A. Lamprecht, B. Heurtault et al. 2006. A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats. Molecular Cancer Therapeutics 5(7):1710-1722.
24. Gasco, M. R. 1993. Method for producing solid lipid microspheres having a narrow size distribution. U.S. Patent:5 250 236.
25. Gelperina, S., K. Kisich, M. D. Iseman, and L. Heifets. 2005. The potential advantage of nanoparticle drug delivery systemin chemotherapy of tuberculosis. American Journal of Respiratory and Critical Care Medicine 172(12):1487-1490.
26. Gibaud, S., M. Demoy, J. P. Andreux et al. 1996. Cells involved in the capture of nanoparticles in hematopoietic organs. Journal of Pharmaceutical Sciences 85(9):944-950.
27. Gopferich, A. 1996. Mechanisms of polymer degradation and erosion. Biomaterials 17(2):103-114.
28. Hans, M. L. and A. M. Lowman. 2002. Biodegradable nanoparticles for drug delivery and targeting. Current Opinion in Solid State and Materials Science 6(4):319-327.
29. Harris, J. M. 1992. Poly(ethylene glycol) Chemistry: Biotechnical and Biomedical Applications, 1st edn. New York: Springer.
30. Heurtault, B., P. Saulnier, B. Pech, J. E. Proust, and J. P. Benoit. 2002. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharmaceutical Research 19(6):875-880.
31. Hillery, A. M. and A. T. Florence. 1996. The effect of adsorbed poloxamer 188 and 407 surfactants on the intestinal uptake of 60-nm polystyrene particles after oral administration in the rat. International Journal of Pharmaceutics 132:123-130.
32. Hou, D., C. Xie, K. Huang, and C. Zhu. 2003. The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials 24(10):1781-1785.
33. Hughes, G. A. 2005. Nanostructure-mediated drug delivery. Nanomedicine 1(1):22-30.
34. Huynh, N. T., C. Passirani, P. Saulnier, and J. P. Benoit. 2009. Lipid nanocapsules: A new platform for nanomedicine. International Journal of Pharmaceutics 379(2):201-209.
35. Italia, J. L., D. K. Bhatt, V. Bhardwaj, K. Tikoo, and M. N. Kumar. 2007. PLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. Journal of Controlled Release 119(2):197-206.
36. Junghanns, J. U. and R. H. Müller. 2008. Nanocrystal technology, drug delivery and clinical applications. International Journal of Nanomedicine 3(3):295-309.
37. Keck, C. M. and R. H. Muller. 2006. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. European Journal of Pharmaceutics and Biopharmaceutics 62(1):3-16.
38. Khalid, M. N., P. Simard, D. Hoarau, A. Dragomir, and J. C. Leroux. 2006. Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors. Pharmaceutical Research 23(4):752-758.
39. Lacoeuille, F., F. Hindre, F. Moal et al. 2007. in vivo evaluation of lipid nanocapsules as a promising colloidal carrier for paclitaxel. International Journal of Pharmaceutics 344(1-2):143-149.
40. Lamprecht, A. and J. P. Benoit. 2006. Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. Journal of Controlled Release 112(2):208-213.
41. Lamprecht, A., J. L. Saumet, J. Roux, and J. P. Benoit. 2004. Lipid nanocarriers as drug delivery system for ibuprofen in pain treatment. International Journal of Pharmaceutics 278(2):407-414.
42. Mathiowitz, E., J. S. Jacob, Y. S. Jong et al. 1997. Biologically erodable microspheres as potential oral drug delivery systems. Nature 386(6623):410-414.
43. Merisko-Liversidge, E., P. Sarpotdar, J. Bruno et al. 1996. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharmaceutical Research 13(2):272-278.
44. Mizuma, T., A. Koyanagi, and S. Awazu. 2000. Intestinal transport and metabolism of glucoseconjugated kyotorphin and cyclic kyotorphin: Metabolic degradation is crucial to intestinal absorption of peptide drugs. Biochimica et Biophysica Acta 1475(1):90-98.
45. Moghimi, S. M. and J. Szebeni. 2003. Stealth liposomes and long circulating nanoparticles: Critical issues in pharmacokinetics, opsonization and protein-binding properties. Progress in Lipid Research 42(6):463-478.
46. Mufamadi, M. S., V. Pillay, Y. E. Choonara et al. 2011. A review on composite liposomal technologies for specialized drug delivery. Journal of Drug Delivery 2011:Article ID 939851 (19pp).
47. Mukherjee, S., R. N. Ghosh, and F. R. Maxfield. 1997. Endocytosis. Physiological Reviews 77(3):759-803.
48. Mukherjee, B., B. Patra, B. Layek, and A. Mukherjee. 2007. Sustained release of acyclovir from nano-liposomes and nano-niosomes: An in vitro study. International Journal of Nanomedicine 2(2):213-225.
49. Müller, R. H., R. Becker, B. Kruss, and K. Peters. 1999. Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution. In United States Patent. USA: Medac, Gesellschaft Fur Klinische Spezialpraparate, Hamburg, Germany.
50. Olbrich, C., N. Scholer, K. Tabatt, O. Kayser, and R. H. Müller. 2004. Cytotoxicity studies of Dynasan 114 solid lipid nanoparticles (SLN) on RAW 264.7 macrophages-impact of phagocytosis on viability and cytokine production. Journal of Pharmacy and Pharmacology 56(7):883-891.
51. Peltier, S., J. M. Oger, F. Lagarce, W. Couet, and J. P. Benoit. 2006. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharmaceutical Research 23(6):1243-1250.
52. Rathbun, R. C., S. M. Lockhart, and J. R. Stephens. 2006. Current HIV treatment guidelines-An overview. Current Pharmaceutical Design 12(9):1045-1063.
53. Roco, M. C. 2011. The long view of nanotechnology development: The National Nanotechnology Initiative at 10 years. Journal of Nanoparticle Research 13:427-445.
54. Russell-Jones, G. J. 2004. Use of targeting agents to increase uptake and localization of drugs to the intestinal epithelium. Journal of Drug Targeting 12(2):113-123.
55. Russell-Jones, G., K. McTavish, J. McEwan, J. Rice, and D. Nowotnik. 2004. Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours. Journal of Inorganic Biochemistry 98(10):1625-1633.
56. Saupe, A. and T. Rades. 2006. Solid lipid nanoparticles. In Nanocarrier Technologies: Frontiers of Nanotherapy, M. R. Mozafari (ed.), Dordrecht, the Netherlands: Springer.
57. Serpe, L., M. G. Catalano, R. Cavalli et al. 2004. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. European Journal of Pharmaceutics and Biopharmaceutics 58(3):673-680.
58. Shegokar, R., K. K. Singh, and R. H. Müller. 2011. Production & stability of stavudine solid lipid nanoparticles-From lab to industrial scale. International Journal of Pharmaceutics 416(2):461-470.
59. Sosnik, A., A. M. Carcaboso, R. J. Glisoni, M. A. Moretton, and D. A. Chiappetta. 2010. New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery. Advanced Drug Delivery Reviews 62(4-5):547-559.
60. Speiser, P. P. 1998. Poorly soluble drugs: A challenge in drug delivery. In Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs, Muller, R. H., S. Benita, and B. H. L. Bohm. Stuttgart, Germany: MedPharm Scientific Publishers.
61. Suman, K., V. S. R. P. Chandrasekhar, and S. Balaji. 2009. Drug nanocrystals: A novel formulation approach for poorly soluble drugs. International Journal of PharmTech Research 1(3):682-694.
62. Thies, J. and B. W. Müller. 1998. Size controlled production of biodegradable microparticles with supercritical gases. European Journal of Pharmaceutics and Biopharmaceutics 45(1):67-74.
63. Violante, M. R. and Fischer; H. W. 1991. Method for making uniformly-sized particles from insoluble compounds. In United States Patent. Rochester, NY: The University of Rochester.
64. Vishnu, P. and V. Roy. 2011. Safety and efficacy of nab-paclitaxel in the treatment of patients with breast cancer. Breast Cancer: Basic and Clinical Research 5:53-65.
65. Xie, H. and J. W. Smith. 2010. Fabrication of PLGA nanoparticles with a fluidic nanoprecipitation system. Journal of Nanobiotechnology 8:18 (7pp).
66. Yeh, P., H. Ellens, and P. L. Smith. 1998. Physiological considerations in the design of particulate dosage forms for oral vaccine delivery. Advanced Drug Delivery Reviews 34(2-3):123-133.
67. Zara, G. P., R. Cavalli, A. Fundaro et al. 1999. Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharmaceutical Research 40(3):281-286.
68. Zucker, D., D. Marcus, Y. Barenholz, and A. Goldblum. 2009. Liposome drug’s loading efficiency: A working model based on loading conditions and drug’s physicochemical properties. Journal of Controlled Release 139(1):73-80.